Matches in Wikidata for { <http://www.wikidata.org/entity/Q64189283> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q64189283 description "clinical trial" @default.
- Q64189283 description "ensayu clínicu" @default.
- Q64189283 description "klinisch onderzoek" @default.
- Q64189283 description "клінічне випробування" @default.
- Q64189283 name "Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)" @default.
- Q64189283 type Item @default.
- Q64189283 label "Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)" @default.
- Q64189283 prefLabel "Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)" @default.
- Q64189283 P1132 Q64189283-CB89A7F4-3390-48D9-B390-C1039EC20AD5 @default.
- Q64189283 P131 Q64189283-07592195-AB17-42E9-B475-3CE3D3C6A644 @default.
- Q64189283 P1476 Q64189283-3D8F2CB9-860C-484E-AE70-736DC5CD85A8 @default.
- Q64189283 P17 Q64189283-1801514A-AE61-4E76-A255-A186B9ACA064 @default.
- Q64189283 P17 Q64189283-61AA2D59-B9D9-4B3A-ABFA-461F080EB136 @default.
- Q64189283 P17 Q64189283-771B7CAA-D46E-4728-A9D0-5F51F902E69A @default.
- Q64189283 P17 Q64189283-ACEE7740-4F41-4937-983D-1848100B59F0 @default.
- Q64189283 P17 Q64189283-C1FECABA-6BE7-4060-9525-45390337D86E @default.
- Q64189283 P17 Q64189283-CCA816B8-68E6-4AE8-99A2-7C6A1941C888 @default.
- Q64189283 P17 Q64189283-E7E52CBC-5147-4A68-AFC9-655218805C48 @default.
- Q64189283 P17 Q64189283-F869F5D3-7149-4613-8816-B472CF5FF374 @default.
- Q64189283 P1813 Q64189283-6AE06682-C666-4072-BA9E-4174200D53FB @default.
- Q64189283 P2899 Q64189283-3BD0E62C-0350-449E-B7DB-058AA638C1AB @default.
- Q64189283 P3098 Q64189283-BC79281A-36F8-4F63-8FDF-70743BDE3D2B @default.
- Q64189283 P31 Q64189283-1CC73C20-4379-4DDC-ADC0-44E2E44C251B @default.
- Q64189283 P4135 Q64189283-C6DE30C1-9FB7-4409-A4DC-CD85FF738A88 @default.
- Q64189283 P4844 Q64189283-7FF0F327-B33E-4594-9608-6F592F77A94E @default.
- Q64189283 P580 Q64189283-D04196C5-EEE5-47C6-877B-62F1546AD580 @default.
- Q64189283 P582 Q64189283-2D70A5F8-613B-49BF-AE9E-29C1AE8ECEC0 @default.
- Q64189283 P6099 Q64189283-48359173-3516-40B7-ABEA-42C8C5F9EA11 @default.
- Q64189283 P8363 Q64189283-9161F57E-C044-43D7-87BA-11D056447006 @default.
- Q64189283 P1132 "+474" @default.
- Q64189283 P131 Q8646 @default.
- Q64189283 P1476 "A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers" @default.
- Q64189283 P17 Q142 @default.
- Q64189283 P17 Q145 @default.
- Q64189283 P17 Q17 @default.
- Q64189283 P17 Q219 @default.
- Q64189283 P17 Q30 @default.
- Q64189283 P17 Q43 @default.
- Q64189283 P17 Q865 @default.
- Q64189283 P17 Q869 @default.
- Q64189283 P1813 "TOPAZ-1" @default.
- Q64189283 P2899 "+18" @default.
- Q64189283 P3098 "NCT03875235" @default.
- Q64189283 P31 Q30612 @default.
- Q64189283 P4135 "+130" @default.
- Q64189283 P4844 Q412415 @default.
- Q64189283 P580 "2019-04-16T00:00:00Z" @default.
- Q64189283 P582 "2022-03-15T00:00:00Z" @default.
- Q64189283 P6099 Q42824827 @default.
- Q64189283 P8363 Q78089383 @default.